Navigation Links
EyeIC Receives FDA 510(k) Clearance for MatchedFlicker(TM) Retinal Aid Detection Technology
Date:6/10/2009

New technology to address issue of interpretation, storage and documentation of photograph files focused on progression of glaucoma

NARBERTH, Pa., June 10 /PRNewswire/ -- EyeIC, an innovator of eye care solutions for ophthalmologists and optometrists, announced today that its MatchedFlicker(TM) technology has received FDA 510(k) clearance from the United States Food & Drug Administration (FDA). MatchedFlicker is a device-agnostic, software-only solution that uses time series retinal photographs to help doctors monitor the advent and progress of glaucoma faster and with accuracy now available to only a few experts.

The technology enables eye care professionals to compare two retinal images taken at different visits from the same patient -- from nearly any source -- and see change brought to life as motion. After the doctors make their evaluations, they have the ability to mark the changes on the flicker and on the images. The software also translates markings made on any image in a Flicker project to the appropriate location on all other images in the same project. All images and annotations are saved in an electronic format and can be printed.

"We are very optimistic that our MatchedFlicker technology will address the pervasive problem of early change detection in glaucoma," said Ira Wallace, CEO of EyeIC. "Currently, the gold standard for detecting retinal changes is done by glaucoma trained experts that compare separate pairs of stereo photos side by side, which makes it difficult to find and document changes between images. MatchedFlicker provides eye care professionals with a technology for faster detection, improved documentation and an easy-to-use electronic format that enables collaboration among multiple doctors across town or across the globe."

EyeIC's technology is an aid to change detection that addresses a rapidly growing market for glaucoma monitoring. In the U.S., glaucoma is the second leading cause of irreversible blindness with 10% of the population over the age of 40 at risk (World Glaucoma Association). It is estimated that over four million Americans have glaucoma, but only half of those know they have it (Prevent Blindness America). The U.S. Department of Labor estimates approximately 56,000 eye care professionals in the U.S. today.

"EyeIC's MatchedFlicker offers ophthalmologists a powerful new tool for the detection of progressive glaucoma," said Nathan Radcliffe, M.D., Director of Glaucoma at Weill Cornell Medical College and New York-Presbyterian Hospital. "MatchedFlicker automatically aligns and alternates serial optic disc photographs, allowing the clinician to quickly inspect each photographic set for small changes of the neuroretinal rim and vasculature."

Radcliffe added, "Subtle features that might escape detection on side by side review of photographs, such as faint disc hemorrhages or peripapillary atrophy progression, can be spotted easily and in a matter of seconds. The software package is intuitive to use and offers a variety of mark-up tools that facilitate report generation and will work well with most EMRs. In my practice, MatchedFlicker has allowed me to make excellent use of historical optic nerve photos and plays a unique role in the detection of progressive glaucoma."

EyeIC was founded in 2004 with a portfolio of intellectual property from the University of Pennsylvania. In November, the company completed a Series A round of $1.9 million in fundraising from MentorTech Ventures, Ben Franklin Technology Partners, private investors and its founder.

"We are extremely pleased with EyeIC's the 510(k) clearance for MatchedFlicker," said Michael B. Aronson, a Board Member of the Company and Managing Director of MentorTech Ventures. "I am impressed by the Company's business model for developing innovative software products that will dramatically improve the diagnostic standard of care for a large number of people afflicted with eye disorders."

EyeIC expects to make available a commercial solution that fully integrates into the current workflow of the eye doctor's office by July of 2009. The company will exhibit at the World Glaucoma Congress on July 8-11 in Boston.

About EyeIC

EyeIC is a medical device company focused on eye care solutions. The company has developed its MatchedFlicker(TM) technology that allows eye care professionals to better monitor the progression of glaucoma and other eye diseases through faster detection and improved interpretation and documentation of retinal photographs. EyeIC was founded in 2004 with a portfolio of intellectual property from the University of Pennsylvania and recently completed a Series A round of $1.9 million in fundraising from MentorTech Ventures, Ben Franklin Technology Partners, private investors and its founder. To learn more, visit www.eyeic.com.

About MentorTech Ventures

MentorTech Ventures invests in information technology, marketing technology, and medical device companies with a focus on those companies with a connection to the University of Pennsylvania. The firm targets seed and early-stage investments, but will opportunistically explore later stage investments. MentorTech typically invests in Philadelphia-based companies, but also makes selective investments outside Philadelphia where it co-invests with other venture firms. The firm seeks to lead the first round of an investment and often takes significant and influential ownership stakes in its portfolio companies. MentorTech Ventures is based in Philadelphia, Pennsylvania.


'/>"/>
SOURCE EyeIC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System
2. Pasteuria Bioscience Receives EPA Registration for Nematode Control
3. D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
4. Yongye Biotechnology International Receives License to Manufacture Products
5. EarlySenses EverOn(TM) System Receives FDA Clearance and CE Mark Certification
6. Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners
7. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
8. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
9. Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. 500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... A recent survey conducted by ... and difficult to control weed in 12 categories of broadleaf crops, fruits and vegetables, ... scientists across the U.S. and Canada participated in the 2016 survey, the second conducted ...
(Date:5/23/2017)... ... May 22, 2017 , ... ... 2017 in San Diego, California, this August will feature high-level speakers on ... autonomous vehicles. , SPIE Optics and Photonics, the largest multidisciplinary optical sciences meeting ...
(Date:5/23/2017)... San Diego, CA (PRWEB) , ... May 23, 2017 , ... ... extracellular matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and ... economic impact of biofilms is in the tens of billions of dollars per year, ...
(Date:5/22/2017)... ... 2017 , ... Baltimore biotech firm, PathSensors, announced that its ... developing and issuing recommendations to grow Maryland's biohealth industry and position the state ... , The recommendations are contained in a report from the Maryland ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):